Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26660446 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL12415404 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6272090 | 0.81 | KMT2A (0.64) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19KMT2A | |
| SCHEMBL1269684 | 0.80 | CYP3A4 (0.67) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL5970008 | 0.80 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2584810 | 0.80 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL26790624 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL14990930 | 0.73 | BRD4 (0.69) | SMN1; SMN2ALDH1A1CYP2C19L3MBTL1KMT2A | |
| SCHEMBL18820798 | 0.72 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| Isophthalic Acid SCHEMBL27639823 | 0.72 | KMT2A (0.55) | SMN1; SMN2ALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | SMN1; SMN2 766/4885ALDH1A1 2142/4885CYP3A4 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.